Oncolytic Virus Embolization for Tumor Necrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viral therapies face challenges in achieving effective tumor-selectivity and potency, particularly when administered intravenously or combined with embolization, due to limitations in virus size and release mechanisms, leading to inefficient tumor penetration and systemic spread.
Innovation Solution
The use of oncolytic Poxviridae or Herpesviridae viruses, such as vaccinia or herpes simplex, combined with biocompatible microparticles or hydrophilic polymer gels like degradable starch, polyvinyl alcohol, or gelatin foam, to enhance viral delivery and retention within tumors during transarterial embolization, preventing systemic spread and increasing viral output by up to 300%.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If oncolytic viruses are administered intravenously or combined with embolization, then viral delivery to tumor is improved, but virus size and release mechanisms limit tumor penetration and cause systemic spread
Solution Approach 1:
The virus is segmented into two functional components: an oncolytic virus core that replicates selectively in tumor cells, and an immunomodulatory protein component that enhances antitumor immunity. This segmentation allows the viral vector to be optimized for tumor targeting while the protein component provides localized immune activation, reducing systemic effects
Solution Approach 2:
An immunomodulatory protein (such as GM-CSF or other cytokines) is introduced as an intermediary component that mediates the interaction between the virus and the host immune system. This protein is co-administered with or incorporated into the viral vector to enhance local immune responses against tumor cells while minimizing systemic immunotoxicity
2Reliability
If virus size is increased to enhance stability, then viral potency is improved, but tumor penetration efficiency decreases
Solution Approach 1:
The viral vector is engineered with a nested structure where the oncolytic virus genome is packaged within a protective capsid that contains embedded immunomodulatory proteins or RNA. This nested arrangement protects the viral components during circulation (improving stability) while maintaining a compact size that facilitates tumor cell entry and penetration
Solution Approach 2:
The viral vector parameters are optimized by adjusting the ratio of viral genome to capsid size, modifying surface charge properties, and tuning the stability of viral proteins. These parameter changes enable the virus to maintain sufficient stability for systemic circulation while preserving adequate tumor penetration capability through size and charge optimization
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A~2B
AI summary
The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.